Opendata, web and dolomites

ELEVATE SIGNED

Early detection of cervical cancer in hard-to-reach populations of women through portable and point-of-care HPV testing

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ELEVATE project word cloud

Explore the words cloud of the ELEVATE project. It provides you a very rough idea of what is the project "ELEVATE" about.

populations    point    latin    community    hard    generate    belgium    vaccination    fundamental    elevate    genomic    preventive    adequacy    programs    shown    marketable    health    base    caribbean    hpv    primary    screened    ethnic    screening    implications    made    trained    efficient    85    electrical    care    manufactures    barriers    occurring    understand    participatory    cervical    human    social    combined    conduct    successful    reflection    highlights    sampling    american    differences    team    infections    reducing    investigations    compatible    rapid    infer    hamper    cultural    portugal    global    outlets    integrant    brazil    comprising    disseminate    fourth    worl    4th    cancer    portable    women    risk    lack    relying    science    resource    precancer    societal    experts    incidence    accessible    coverage    reduce    self    worldwide    attendance    detection    proteomic    mortality    strategies    complemented    technological    papillomavirus    economic    burden    multidisciplinary    countries    ecuador   

Project "ELEVATE" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT GENT 

Organization address
address: SINT PIETERSNIEUWSTRAAT 25
city: GENT
postcode: 9000
website: http://www.ugent.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 3˙999˙310 €
 EC max contribution 3˙301˙990 € (83%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT GENT BE (GENT) coordinator 1˙518˙835.00
2    UNIVERSIDADE NOVA DE LISBOA PT (LISBOA) participant 419˙850.00
3    LABMAN AUTOMATION LIMITED UK (MIDDLESBROUGH CLEVELAND) participant 395˙420.00
4    UNIVERSITAT ROVIRA I VIRGILI ES (TARRAGONA) participant 341˙802.00
5    UNIVERSIDAD DE CUENCA EC (CUENCA) participant 259˙900.00
6    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) participant 214˙577.00
7    microLIQUID sl ES (Arrasate-Mondragon) participant 151˙605.00
8    CONSORCIO DE INVESTIGACION SOBRE VIH SIDA TB CISIDAT MX (CUERNAVACA MORELOS) participant 0.00
9    FUNDACAO PIO XII BR (BARRETOS) participant 0.00

Map

 Project objective

Cervical cancer is the 4th most common cancer in women worlThe ELEVATE project sets a multidisciplinary team comprising manufactures and experts from Europe and the Community of Latin American and Caribbean States, to improve the global adequacy and coverage of cervical cancer screening, particularly to specific populations of women that by not being regularly screened (hard-to-reach populations) are at higher-risk to develop cervical cancer. Although Cervical cancer is still the fourth most common cancer in women worldwide, with up to 85% of the burden occurring in developing countries, preventive vaccination against human papillomavirus and early detection of precancer in screening programs has shown to be successful in reducing cancer incidence and mortality.1–3 However, different challenges hamper a global implementation of such programs and are in the base of women’s non-attendance to screening. This highlights the lack of reflection of ethnic, cultural and resource differences from different populations in current cervical cancer screening. In ELEVATE it is proposed to conduct social science investigations to identify hard-to-reach women in Belgium, Brazil, Ecuador and Portugal, to address their barriers to screening and to design strategies to make primary screening more accessible to them, and therefore, contribute to reduce the global burden of cervical cancer. This will be complemented with fundamental and technological research to develop an efficient and marketable test for the combined genomic and proteomic detection of high-risk HPV infections in those populations. The test will be made portable, low-cost, compatible with self-sampling, point-of-care and generate rapid and easy-to-understand results, without relying on electrical outlets or trained health personnel. Integrant part of the proposal is also to infer and disseminate the societal, economic implications of the developed strategies using a hard-to-reach community-based participatory research.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ELEVATE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ELEVATE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More